ClinicalTrials.Veeva

Menu

A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer

H

Haruhiko Fukuda

Status and phase

Terminated
Phase 3

Conditions

Cervical Neoplasms

Treatments

Drug: neoadjuvant chemotherapy + radical hysterectomy
Procedure: radical hysterectomy

Study type

Interventional

Funder types

Other

Identifiers

NCT00190528
C000000194
JCOG0102

Details and patient eligibility

About

To investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II cervical cancer

Full description

We designed this randomized study to investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II cervical cancer. Patients with FIGO stage I/II with bulky disease are randomized to either neoadjuvant chemotherapy (BOMP: Cisplatin 14mg/m2 day 1-5, Bleomycin 7mg day 1-5, Mitomycin 7mg/m2 day 5, and Vincristine 0.7mg/m2 day every 21 days for 2-4 cycles followed by radical hysterectomy or radical hysterectomy alone. The primary endpoint is overall survival and the secondary endpoints are progression-free survival, complication of surgery, completeness of radical hysterectomy, omission of postsurgical irradiation, completeness of postsurgical irradiation, response rate, and adverse events. A total 200 patients (100 per treatment arm) planned to accrue for this study within 5.5 years.

Enrollment

200 patients

Sex

Female

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Untreated cervical cancer
  2. Pathologically diagnosed squamous carcinoma
  3. FIGO stage Ib2, IIa (>4cm), and IIb
  4. Measurable lesions
  5. Possible to radical hysterectomy
  6. Age: 20 to 70 years
  7. PS: 0 and 1
  8. WBC > 3,000/mm3, Hb > 9.0g/dl, Platelet > 100,000 /mm3, SGOT/SGPT < 60 IU/L, T-Bil < 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG
  9. Written informed consent

Exclusion criteria

  1. Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer those are curable with local therapy
  2. Women during pregnancy or breast-feeding
  3. Patients with psychiatric illness
  4. Patients who have active infection
  5. Patients who have uncontrolled diabetes or uncontrolled hypertension
  6. Patients who have positive HBs
  7. Patients who have had heart failure, unstable angina, or myocardial infarction within the past 6 months
  8. Patients with interstitial pneumonitis or pulmonary fibrosis
  9. Patients who are unable to undergo radical hysterectomy for complication of excessive obesity, liver cirrhosis, or bleeding tendency

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

Surgery
Active Comparator group
Treatment:
Procedure: radical hysterectomy
Chemotherapy + Surgery
Experimental group
Treatment:
Drug: neoadjuvant chemotherapy + radical hysterectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems